Elevated IgM Levels and Associated Conditions

Primary Causes of Elevated IgM

Elevated IgM levels are most significantly associated with Waldenström macroglobulinemia (WM) or lymphoplasmacytic lymphoma (LPL), characterized by monoclonal IgM production by lymphoplasmacytic cells infiltrating the bone marrow, according to the National Comprehensive Cancer Network 1, 2.
Autoimmune disorders, such as autoimmune hepatitis, may present with elevated immunoglobulins, though IgG is more commonly elevated than IgM in these cases, as noted by the Journal of Hepatology 3.

The initial evaluation for elevated IgM should include a complete blood count with differential to assess for cytopenias, which may suggest bone marrow infiltration, as recommended by the National Comprehensive Cancer Network 5.
Serum protein electrophoresis (SPEP) and immunofixation (IFE) should be performed to distinguish between monoclonal and polyclonal elevations, according to the Journal of the National Comprehensive Cancer Network 2, 5.

The American Society of Clinical Oncology recommends that asymptomatic patients with monoclonal IgM (MGUS or smoldering WM) should be followed without therapy, as stated in the Annals of Oncology 6.
Treatment indications for Waldenström macroglobulinemia include IgM levels > 60 g/L due to imminent risk of symptomatic hyperviscosity, as recommended by the Annals of Oncology 6.
Response assessment in Waldenström macroglobulinemia uses IgM levels as a key marker, with complete response defined as normal IgM level and absence of monoclonal protein by immunofixation, according to Blood and the Journal of the National Comprehensive Cancer Network 8, 9.

The National Comprehensive Cancer Network notes that rituximab can cause a transient increase in serum IgM (30-80% of patients), which may exacerbate hyperviscosity symptoms but doesn't indicate treatment failure 6, 9.
Regular monitoring of IgM levels is essential for patients with known monoclonal gammopathy or WM to detect disease progression, as recommended by the Journal of the National Comprehensive Cancer Network 2, 9.